COMMUNIQUÉS West-GlobeNewswire

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

11/11/2024 - 22:05

Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering [...]

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

11/11/2024 - 22:05

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients [...]

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

11/11/2024 - 22:05

—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management [...]

Sienna Senior Living Inc. Reports Strong Third Quarter 2024 Financial Results and Continues on its Growth Path

11/11/2024 - 22:15

MARKHAM, Ontario, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and nine months ended September 30, 2024. The [...]

Precision Optics Corporation Schedules First Quarter of Fiscal Year 2025 Conference Call for November 14, 2024

11/11/2024 - 22:15

GARDNER, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]

DBV Technologies annonce son intention de modifier le ratio d'ADS

11/11/2024 - 22:30

Châtillon, France, le 11 novembre (22 :30 CET) 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP:23306J200), [...]

DBV Technologies Announces Plan to Implement ADS Ratio Change

11/11/2024 - 22:30

Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage [...]

Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib)

11/11/2024 - 22:35

LOUISVILLE, Ky., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Genentech, a member of the Roche Group, for ITOVEBI ™ ( [...]

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

11/11/2024 - 22:36

Data show that the NPCCSS swallow score reflects the patient’s level of dysfunction Study indicates that a change in score reflects actual improvement or worsening in a patient’s swallowing function CELEBRATION, Fla., [...]

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

09/11/2024 - 23:30

ALK ( ALKB:DC / OMX: ALK B ) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights [...]

KFSHRC’s New US Patent Opens New Frontiers for Breast Cancer Treatment

10/11/2024 - 13:26

RIYADH, Saudi Arabia, Nov. 10, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) announced a significant advancement in stem cell science, securing a U.S. patent for an innovative [...]

RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA⁽¹⁾ and Revises Upwards 2024 Financial Guidance Ranges

10/11/2024 - 22:15

Total Company Revenue increased 14.7% to $461.1 million in the third quarter of 2024 from $402.0 million in the third quarter of 2023; Revenue from the Digital Health reportable segment (inclusive of intersegment [...]

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

08/11/2024 - 23:00

Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 [...]

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08/11/2024 - 23:30

MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s [...]

Revolutionizing Prescription Management: Ironsail Pharma Launches Advanced Pharmacy Network Technology

08/11/2024 - 23:40

Ironsail Pharma’s mission is to enhance patient outcomes by connecting providers and pharmacies through a technology-driven solution that emphasizes transparency and exceptional service New York, New York, Nov. 08, 2024 [...]

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

09/11/2024 - 16:30

Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by end-of-year NOVATO, Calif., Nov [...]

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

09/11/2024 - 19:00

Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration, and kinetics Initial [...]

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

09/11/2024 - 19:30

Novel H 2 CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable Safety Profile in [...]

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

09/11/2024 - 19:40

Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals [...]